

Filippo Montemurro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9207220/publications.pdf>

Version: 2024-02-01

150
papers

5,277
citations

87723

38
h-index

102304

66
g-index

154
all docs

154
docs citations

154
times ranked

7463
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. <i>Annals of Oncology</i> , 2007, 18, 977-984.	0.6	498
2	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	5.1	441
3	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 67-76.	1.1	225
4	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012, 22, 1519-1528.	2.3	206
5	Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial†. <i>Annals of Oncology</i> , 2020, 31, 1350-1358.	0.6	206
6	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1863-1872.	6.3	164
7	Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. <i>Oncologist</i> , 2006, 11, 318-324.	1.9	116
8	TGFβ± expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005, 24, 3002-3010.	2.6	113
9	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. <i>Annals of Oncology</i> , 2013, 24, 2715-2724.	0.6	106
10	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 257-268.	1.4	96
11	Metastatic breast cancer subtypes and central nervous system metastases. <i>Breast</i> , 2014, 23, 623-628.	0.9	95
12	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. <i>BMC Cancer</i> , 2011, 11, 31.	1.1	86
13	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	1.9	79
14	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
15	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 1740-1748.	0.6	74
16	Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. <i>European Journal of Cancer</i> , 2019, 109, 92-102.	1.3	73
17	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2± Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	7.7	69
18	Safety of everolimus plus exemestane in patients with hormone-receptor±positive, HER2±negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. Expert Opinion on Pharmacotherapy, 2020, 21, 1071-1082.	0.9	62
20	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	5.1	59
21	Hormone receptor expression and activity of trastuzumab with chemotherapy in HER2 positive advanced breast cancer patients. Cancer, 2012, 118, 17-26.	2.0	58
22	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. European Radiology, 2007, 17, 1490-1497.	2.3	56
23	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open, 2017, 2, e000253.	2.0	56
24	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. European Journal of Cancer, 2012, 48, 2311-2318.	1.3	55
25	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. JAMA Oncology, 2016, 2, 445.	3.4	55
26	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	1.6	53
27	Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer. Cell Reports, 2015, 11, 564-576.	2.9	52
28	Biomarkers of drugs targeting HER family signalling in cancer. Journal of Pathology, 2014, 232, 219-229.	2.1	49
29	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
30	A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer. Oncology, 2004, 66, 38-45.	0.9	48
31	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers, 2019, 11, 1661.	1.7	48
32	Immunophenotypic heterogeneity of hyalinizing trabecular tumours of the thyroid. Histopathology, 1997, 31, 525-533.	1.6	47
33	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment, 2011, 130, 29-40.	1.1	47
34	Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients. CardioVascular and Interventional Radiology, 2012, 35, 139-145.	0.9	47
35	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. Acta Oncologica, 2007, 46, 664-668.	0.8	46
36	Trastuzumab-based combination therapy for breast cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 81-96.	0.9	43

#	ARTICLE	IF	CITATIONS
37	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. <i>Oncotarget</i> , 2015, 6, 2315-2330.	0.8	43
38	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 41, 137-143.	0.9	41
39	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	1.3	39
40	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37
41	Metastatic Cancer of Unknown Primary or Primary Metastatic Cancer?. <i>Frontiers in Oncology</i> , 2019, 9, 1546.	1.3	35
42	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. <i>European Radiology</i> , 2005, 15, 1224-1233.	2.3	34
43	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 511-523.	1.1	34
44	Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life. <i>SpringerPlus</i> , 2016, 5, 59.	1.2	33
45	Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
46	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1436-1441.	0.6	31
47	Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1631-1636.	0.6	30
48	Percutaneous Vertebroplasty in Osteoporotic Patients: An Institutional Experience of 1,634 Patients with Long-Term Follow-Up. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1714-1720.	0.2	30
49	Complications of hyperglycaemia with PI3K/AKT/mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. <i>British Journal of Cancer</i> , 2015, 113, 1541-1547.	2.9	30
50	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	1.1	30
51	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. <i>Endocrine-Related Cancer</i> , 2009, 16, 1091-1102.	1.6	29
52	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431.	1.9	29
53	HER2-positive metastatic breast cancer: A changing scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 78-87.	2.0	29
54	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 37, 142-147.	0.9	29

#	ARTICLE	IF	CITATIONS
55	Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Medicine</i> , 2018, 7, 4339-4344.	1.3	29
56	Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 95-97.	0.6	28
57	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 1261-1267.	2.9	27
58	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	1.9	26
59	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442.	1.1	25
60	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014, 23, 44-49.	0.9	25
61	A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features. <i>British Journal of Radiology</i> , 2017, 90, 20170269.	1.0	25
62	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017, 13, 2791-2797.	1.1	23
63	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0,784314, BT /Ov 1137.	1.7	22
64	Efficacy and safety of T-DM1 in the "common-practice"™ of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017, 8, 64481-64489.	0.8	22
65	Incorporating Trastuzumab into the Neoadjuvant Treatment of HER2-Overexpressing Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 77-80.	1.1	21
66	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. <i>Acta Oncologica</i> , 2006, 45, 216-217.	0.8	21
67	Linifanib: current status and future potential in cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 677-687.	1.1	21
68	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
69	Continuation of Trastuzumab Beyond Disease Progression. <i>Journal of Clinical Oncology</i> , 2005, 23, 2866-2868.	0.8	20
70	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	0.7	20
71	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	2.1	20
72	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. <i>Nature Communications</i> , 2021, 12, 2498.	5.8	20

#	ARTICLE	IF	CITATIONS
73	Variation of Breast Vascular Maps on Dynamic Contrast-Enhanced MRI After Primary Chemotherapy of Locally Advanced Breast Cancer. <i>American Journal of Roentgenology</i> , 2011, 196, 1214-1218.	1.0	19
74	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1203.	3.4	19
75	Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 85-95.	1.1	18
76	HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. <i>Oncology Reports</i> , 2005, 13, 305-9.	1.2	18
77	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. <i>Journal of Pathology</i> , 2013, 229, 390-399.	2.1	16
78	Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. <i>Breast</i> , 2018, 38, 160-164.	0.9	16
79	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
80	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2052-2053.	0.8	13
81	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. <i>BMC Cancer</i> , 2010, 10, 28.	1.1	13
82	Clinical utility of exemestane in the treatment of breast cancer. <i>International Journal of Women's Health</i> , 2015, 7, 551.	1.1	13
83	Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. <i>Radiologia Medica</i> , 2003, 106, 51-8.	4.7	13
84	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. <i>Annals of Oncology</i> , 2007, 18, 1963-1968.	0.6	12
85	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. <i>Oncology Letters</i> , 2012, 3, 819-824.	0.8	12
86	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 131.	1.0	12
87	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 241-245.	0.4	12
88	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
89	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. <i>ESMO Open</i> , 2020, 5, e000876.	2.0	12
90	Trastuzumab Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2186-2186.	13.9	11

#	ARTICLE	IF	CITATIONS
91	Vertebral Augmentation with Nitinol Endoprosthesis: Clinical Experience in 40 Patients with 1-Year Follow-up. CardioVascular and Interventional Radiology, 2014, 37, 193-202.	0.9	11
92	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. Expert Review of Anticancer Therapy, 2016, 16, 211-218.	1.1	11
93	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Drug Design, Development and Therapy, 2021, Volume 15, 2711-2720.	2.0	11
94	HER2 and Central Nervous System Metastasis in Patients with Breast Cancer. Clinical Breast Cancer, 2004, 5, 232-234.	1.1	10
95	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2566-2567.	0.8	10
96	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLEET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. Oncologist, 2017, 22, 648-654.	1.9	10
97	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. ESMO Open, 2020, 5, e000937.	2.0	10
98	Cancer of Unknown Primary (<scp>CUP</scp>): genetic evidence for a novel nosological entity? A case report. EMBO Molecular Medicine, 2020, 12, e11756.	3.3	10
99	Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability. Breast Cancer Research and Treatment, 2003, 82, 185-190.	1.1	9
100	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy, 2011, 12, 549-565.	0.9	9
101	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 2179-2189.	0.9	9
102	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer, 2008, 8, 209.	1.1	8
103	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer: Targets and Therapy, 2010, 2, 93.	1.0	8
104	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. Oncologist, 2010, 15, 665-672.	1.9	8
105	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer. Cancer Treatment Reviews, 2016, 48, 1-7.	3.4	8
106	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. European Journal of Cancer, 2018, 105, 61-70.	1.3	8
107	Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?. Lancet Oncology, The, 2020, 21, 21-24.	5.1	8
108	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget, 2016, 7, 4442-4453.	0.8	8

#	ARTICLE	IF	CITATIONS
109	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. <i>Clinical Breast Cancer</i> , 2000, 1, 197-209.	1.1	7
110	Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 330-340.	2.0	7
111	What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 5-9.	0.9	7
112	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156.	0.9	6
113	Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. <i>Breast</i> , 2014, 23, 690-691.	0.9	6
114	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019, 25, 444-449.	0.4	6
115	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	1.3	6
116	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	2.3	6
117	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. <i>Cancer</i> , 2005, 103, 1314-1315.	2.0	5
118	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072.	0.9	5
119	Trastuzumab Beyond Disease Progression: Case Closed?. <i>Journal of Clinical Oncology</i> , 2009, 27, e121-e122.	0.8	5
120	Trastuzumab emtansine in HER2-positive metastatic breast cancer. <i>Lancet Oncology</i> , The, 2017, 18, 696-697.	5.1	5
121	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	2.0	5
122	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLETT study. <i>Oncotarget</i> , 2020, 11, 2172-2181.	0.8	5
123	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 2468.	1.7	5
124	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011, 25, 1545-8.	1.2	4
125	Treating breast cancer with cell-based approaches: an overview. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1255-1264.	1.4	4
126	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	0.9	4

#	ARTICLE	IF	CITATIONS
127	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
128	Duration of trastuzumab for HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 678-679.	5.1	3
129	Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 393-403.	1.9	3
130	A new player in the treatment of HER2-positive tumours. <i>Lancet Oncology</i> , The, 2019, 20, 748-750.	5.1	3
131	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 398-399.	4.3	2
132	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	1.1	2
133	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2016, 1, e000109.	2.0	2
134	Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study. <i>Cancers</i> , 2020, 12, 327.	1.7	2
135	Breast cancer in BRCA mutation carriers: medical treatment. <i>Minerva Ginecologica</i> , 2016, 68, 557-65.	0.8	2
136	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. <i>Oncologist</i> , 2011, 16, 534-536.	1.9	1
137	Upfront adjuvant aromatase inhibitors in women with lobular breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3376-3377.	1.3	1
138	HER2 expression and efficacy of T-DM1. <i>Breast Cancer Research</i> , 2014, 16, 478.	2.2	1
139	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	0.6	1
140	Target achieved. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1047-1048.	0.9	0
141	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1179-1188.	0.9	0
142	Reply to A. Sánchez-Muñoz et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e257-e258.	0.8	0
143	Anthracycline-based adjuvant chemotherapy in breast cancer. <i>Lancet</i> , The, 2010, 375, 1871.	6.3	0
144	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Imaging as a potential tool for subtyping breast cancer. <i>Imaging in Medicine</i> , 2012, 4, 577-579.	0.0	0
146	2013 San Antonio Breast Cancer Symposium. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1191-1195.	0.9	0
147	Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1039-1041.	0.9	0
148	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	0.8	0
149	Neoadjuvant Therapy in Breast Cancer. , 2012, , 95-108.		0
150	The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. <i>Cells</i> , 2022, 11, 1944.	1.8	0